Profile of prostatic-specific antigen in prostatic carcinomas

Area of Science:

• Oncology
• Biochemistry
• Urology

Background:

• Prostatic carcinomas (PCs) are categorized as latent or clinical, correlating with histologic grade and prostatic specific antigen (PSA) levels.
• Understanding quantitative and qualitative PSA differences is crucial for PC diagnosis and staging.

Purpose of the Study:

• To investigate quantitative and qualitative differences in prostatic specific antigen (PSA) within prostatic carcinomas (PCs) relative to Gleason's histologic grade.
• To identify specific PSA characteristics associated with different grades of PC.

Main Methods:

• Radiometric assay of PSA concentration in tissue cytosol from PCs and normal/hyperplastic prostate tissue.
• Western blotting of cytosol using polyclonal and monoclonal antibodies against PSA, prostatic acid phosphatase, and beta-microseminoprotein.

Main Results:

• PCs, especially high-grade ones, exhibited lower PSA concentrations compared to normal and hyperplastic prostate tissues.
• Western blotting revealed distinct immunoreactive PSA bands in cancerous versus non-cancerous cytosols.
• Reduced PSA concentration and altered PSA immunoblotting patterns were characteristic of PCs, particularly those with Gleason grades >7.

Conclusions:

• Quantitative and qualitative PSA alterations are indicative of prostatic carcinomas (PCs).
• These PSA changes are more pronounced in higher-grade PCs (Gleason grade >7), suggesting a link to aggressive disease.
• PSA analysis, including immunoblotting, can aid in differentiating PCs from benign prostate conditions.